New study tests ocrelizumab in underrepresented MS patients
NCT ID NCT04377555
First seen Nov 17, 2025 · Last updated May 05, 2026 · Updated 23 times
Summary
This study tested the drug ocrelizumab in 179 Black and Hispanic patients with relapsing multiple sclerosis. The goal was to see how well the drug controls disease activity and nerve damage over 48 weeks. Participants received ocrelizumab and were monitored for relapses, disability progression, and brain lesions on MRI.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta Neuroscience Institute
Atlanta, Georgia, 30327, United States
-
Baptist Neurology - Beaches
Jacksonville Beach, Florida, 32250, United States
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
Baylor College of Medicine Medical Center
Houston, Texas, 77030, United States
-
Centro Internacional De Mercadeo
Guaynabo, 969, Puerto Rico
-
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Guilford Neurologic Research Partners, LLC
Greensboro, North Carolina, 27401, United States
-
Hackensack University Medical Center
Paramus, New Jersey, 07652, United States
-
Jefferson University Hospitals, Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Johns Hopkins University Neurology Research Office
Baltimore, Maryland, 21287, United States
-
Josephson Wallack Munshower Neurology PC
Indianapolis, Indiana, 46256, United States
-
Keck School of Medicine of USC
Los Angeles, California, 90033-5315, United States
-
Multiple Sclerosis Center of Tidewater
Norfolk, Virginia, 23502, United States
-
Neurology Clinic - Cordova
Cordova, Tennessee, 38018, United States
-
North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
Frisco, Texas, 75034, United States
-
Rush University Medical Center
Chicago, Illinois, 60612-3244, United States
-
SUNY Upstate Medical Center
Syracuse, New York, 13210, United States
-
Shepherd Center Inc.
Atlanta, Georgia, 30309, United States
-
The Aga Khan University-Kenya.
Nairobi, 00100, Kenya
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201-1642, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37204, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Wayne State University
Detroit, Michigan, 48201, United States
-
Wheaton Franciscan Healthcare - St. Francis Outpatient Center
Milwaukee, Wisconsin, 53215, United States
Conditions
Explore the condition pages connected to this study.